Tag: asco conference 2022
Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%?
Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%?
Braftovi shows a higher response rate in a triplet combination after adding Opdivo. Shifting focus towards microsatellite stable metastatic colorectal cancer (MSS CRC) patients
Braftovi shows a higher response rate in a triplet combination after adding Opdivo. Shifting focus towards microsatellite stable metastatic colorectal cancer (MSS CRC) patients
Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated durable responses in the earlier setting of Multiple Myeloma: Updated findings from the CARTITUDE-2 trial
Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated durable responses in the earlier setting of Multiple Myeloma: Updated findings from the CARTITUDE-2 trial
Gilead in trouble waters as Trodelvy shows below par response in 3L+ HR+/HER2- Breast Cancer Setting
Gilead in trouble waters as Trodelvy shows below par response in 3L+ HR+/HER2- Breast Cancer Setting
Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metastatic Breast Cancer
Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metastatic Breast Cancer
Enhertu carving out a new space for itself in HER2 low patients. A major-label expansion is likely on the way
Enhertu carving out a new space for itself in HER2 low patients. A major-label expansion is likely on the way
Yet another failure in treating Small-Cell Lung Cancer as Roche's much-anticipated anti-TIGIT immunotherapy fails in Phase III
Yet another failure in treating Small-Cell Lung Cancer as Roche's much-anticipated anti-TIGIT immunotherapy fails in Phase III
Consistent Results Across All Sub-Groups Seen in the Newly Launched First in Class LAG-3 Combination Drug Opdualag
Consistent Results Across All Sub-Groups Seen in the Newly Launched First in Class LAG-3 Combination Drug Opdualag
Encouraging results of nivolumab + bevacizumab + FOLFOXIRI in patients with RAS/BRAF mutations as a 1st Line treatment option
Encouraging results of nivolumab + bevacizumab + FOLFOXIRI in patients with RAS/BRAF mutations as a 1st Line treatment option
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022
The PROs Further Support Durvalumab + Chemo in Becoming The New Standard of Care in 1st Line Advanced Biliary Tract Cancer
The PROs Further Support Durvalumab + Chemo in Becoming The New Standard of Care in 1st Line Advanced Biliary Tract Cancer
Making Way For Immunotherapy In The GI Cancers, Durvalumab To Become The New Standard of Care For Advanced Biliary Tract Cancers
Making Way For Immunotherapy In The GI Cancers, Durvalumab To Become The New Standard of Care For Advanced Biliary Tract Cancers
With modest efficacy, Neratinib Continues To Be A Potential Treatment Option For HER2+ive Biliary Tract Cancers
With modest efficacy, Neratinib Continues To Be A Potential Treatment Option For HER2+ive Biliary Tract Cancers
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post success in the HER3 Breast Cancer Trial
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post success in the HER3 Breast Cancer Trial
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic HNSCC. CRL issued on Nasopharyngeal Carcinoma could prove to be a setback?
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic HNSCC. CRL issued on Nasopharyngeal Carcinoma could prove to be a setback?
